Abbott Laboratories (FRA:ABL)
Germany · Delayed Price · Currency is EUR | Market Cap | 143.11B -30.4% |
| Revenue (ttm) | 39.14B +6.6% |
| Net Income | 5.42B -53.5% |
| EPS | 3.10 -53.6% |
| Shares Out | n/a |
| PE Ratio | 26.39 |
| Forward PE | 16.69 |
| Dividend | 2.09 (2.54%) |
| Ex-Dividend Date | Apr 15, 2026 |
| Volume | 238 |
| Open | 77.58 |
| Previous Close | 77.38 |
| Day's Range | 77.58 - 87.82 |
| 52-Week Range | 69.76 - 116.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 16, 2026 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, h... [Read more]
Financial Performance
In 2025, Abbott Laboratories's revenue was $44.33 billion, an increase of 5.67% compared to the previous year's $41.95 billion. Earnings were $6.50 billion, a decrease of -51.49%.
Financial numbers in USD Financial StatementsNews
Abbott’s Q2 gives confidence in improving results, says William Blair
William Blair reiterated an Outperform rating on Abbott (ABT) Laboratories, noting that the shares traded up over 10% on Q2 results that help alleviate concerns about medtech end-markets, the recent…
Abbott Laboratories Stock (ABT) Rallies on a Q2 Earnings Beat and a 2026 EPS Guidance Increase
Abbott Laboratories stock took off on Thursday after the company posted strong earnings and updated its EPS guidance.
Abbott Laboratories Earnings Call Transcript: Q2 2026
Second quarter sales grew 4.8% with adjusted EPS of $1.31, exceeding expectations. Full-year sales growth guidance was reaffirmed and EPS guidance raised, with strong momentum in nutrition, diagnostics, and medical devices. Key product launches and pipeline investments support future growth.
Abbott Laboratories Earnings release: Q2 2026
Abbott Laboratories released its Q2 2026 earnings on July 16, 2026, summarizing the period's financial results.
Abbott Laboratories Slides: Q2 2026
Abbott Laboratories has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 16, 2026.
Abbott Laboratories Sales Rise on Diagnostics Growth
The healthcare company said its profit fell to $928 million, or 53 cents a share, in the second quarter, from $1.78 billion, or $1.01 a share, a year earlier.
Abbott reports Q2 adjusted EPS $1.31, consensus $1.28
Reports Q2 revenue $12.59B, consensus $12.52B. “Our second-quarter results reflect the momentum we are building,” said Robert B. Ford, chairman and chief executive officer, Abbott (ABT). “We expect th...
Abbott raises FY26 adjusted EPS view to $5.45-$5.60 from $5.38-$5.58
FY26 consensus $5.48. Abbott (ABT) projects full-year 2026 comparable sales growth of 6.5% to 7.5%, consensus $50.26B.
Abbott sees Q3 adjusted EPS $1.38-$1.46, consensus $1.42
07:33 EDT Abbott (ABT) sees Q3 adjusted EPS $1.38-$1.46, consensus $1.42
Abbott raises 2026 profit forecast on heart device strength
Abbott raised its annual profit forecast on Thursday, as it expects strong demand for its heart devices in the second half of the year.
Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
Second-quarter reported sales growth of 13.0 percent; comparable sales growth of 4.8 percent Second-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.31 Abbott reaffirms full-year 2026 com...
2 ‘Strong Buy’ Dividend Aristocrat Stocks to Grab Right Now for August Payouts
AbbVie ($ABBV) and Abbott Laboratories ($ABT) are two Dividend Aristocrat stocks with a Strong Buy consensus rating on Wall Street and an ex-dividend date of July 15, according to the…
Abbott price target lowered to $112 from $120 at Evercore ISI
Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Abbott (ABT) to $112 from $120 and keeps an Outperform rating on the shares. The firm’s Q2 preview for…
Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.
This relationship between inflation and value stocks' outperformance is often overlooked. Many investment experts mistakenly believe that a strong economy, not inflation, is the key to value stocks be...
US DOJ closes criminal probe into Abbott over baby formula plant, WSJ reports
The U.S. Justice Department closed a criminal probe into Abbott Laboratories over how it managed a baby formula facility where potentially deadly bacteria were discovered and suspected of cau...
The Baby Formula Probe Produced a Pile of Evidence. Then the DOJ Dropped the Case.
WASHINGTON—The Justice Department spent years investigating Abbott Laboratories ABT 0.94%increase; up pointing triangle over how it managed a baby formula facility where potentially deadly bacteria wa...
Abbott hosts conference call for second-quarter earnings
ABBOTT PARK, Ill., June 25, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2026 financial results on Thursday, July 16, before the market opens.
ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing
ALZpath Strengthens Market Leadership with Abbott Agreement to Help Enable Early Alzheimer's Diagnosis at Global Scale CARLSBAD, Calif., June 24, 2026 /PRNewswire/ -- ALZpath Inc., the leader in bloo...
ALZpath signs licensing deal with Abbott to develop Alzheimer's blood test
ALZpath said on Wednesday it had signed a global licensing agreement with Abbott Laboratories to help advance blood-based testing for Alzheimer's disease, as companies race to offer easier-to-use di...
Missouri appeals court won't send Abbott's appeal of $495 million preterm baby formula verdict to higher court
A Missouri appeals court on Monday declined to send Abbott Laboratories' appeal of a $495 million verdict in a case claiming the company's specialized formula for premature infants caused an Illinoi...
New Similac® survey finds social media pressure to be "perfect" is fueling a shift toward authenticity for the next generation of parents
Despite optimism about parenthood, unrealistic online portrayals are adding pressure for today's young parents Through the new "Love Without Measure" initiative, Similac is standing with parents in pr...
Living Longer Is Big Business. These Stocks Will Benefit.
TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.
